Development of a lead candidate for the treatment of alzheimer's disease
Ended Project Grant Awarded Last action
- Award ID
- R41AG079775
- Recipient
-
Vova IDA Therapeutics, Inc. UEI D2EMMGPZM539
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $100,250
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date
- Originally
- Place of performance
- Jupiter, FL 33458, USA
Award details come from USAspending.gov.
Description
- Abstract
- Alzheimer's disease (ad) is an age-related neurodegenerative disease that has become a global epidemic with over 40 million people affected worldwide and a projected 115 million in 2050. IT is the 6TH leading cause of death in the united states. Ad has a tremendous impact on health, society and the economy. Approved treatments at best partially ameliorate some symptoms. There is an urgent need for novel, disease-modifying treatments. Ad is a complex disease with multiple players that may be targeted for therapeutic intervention. A core pathogenic mechanism is the cellular toxicity of AB42 peptide oligomers with the cascade of activation and phosphorylation events that follow neuronal oligomeric AB42 binding and internalization. These result, inter alia, in oxidative stress, mitochondrial dysfunction, synaptic dysfunction, abnormal CA2+ signaling and excitotoxicity. The overarching goal of this project is to develop a drug targeting neurotoxic AB42 signaling. In this phase 1 component of the project, we will demonstrate the feasibility of optimizing our candidate compound into a therapeutic lead. We will conduct several rounds of structure-activity relationship studies aimed at increasing the compound's potency, selectivity, metabolic and pharmacokinetic properties, including brain penetration. A series of in vitro/cell-based assays, dmpk studies and testing in a murine ad model will guide compound progression. The successful completion of phase 1 will deliver an optimized lead compound ready for development and IND-enabling studies in phase 2.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $100,250 | |
| Amendment | $0 | |
| Original award | $0 |
Quick answers
Who received award R41AG079775?
R41AG079775 was awarded to Vova IDA Therapeutics, Inc. by National Institute on Aging (National Institutes of Health) on September 30, 2022.
How much is award R41AG079775 worth?
$100,250 has been obligated on R41AG079775.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award